Aurion Biotech

Greg Kunst, CEO 

Oct. 11 | 5:00pm | Rentschler ATMP Ballroom 

Seattle, WA 


Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company’s first candidate is for the treatment of corneal edema secondary to corneal endothelial disease, and is the first allogenic, clinically validated cell therapy for corneal endothelial disease, having received regulatory approval in Japan. The company will initiate Phase 1 clinical trials in the U.S. in the second half of 2023. Aurion Biotech is a privately held company backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions